Fertility startup Inito has raised 29 million dollars in Series B funding. This investment will scale its at-home health diagnostics platform and support the use of AI-designed antibodies to create new kinds of at-home tests.
When the company launched its first fertility monitor in 2021, its goal was to make quantitative fertility hormone testing possible at home. Standard at-home ovulation tests predict fertile days by tracking estrogen and Luteinizing hormone, but they do not measure the hormone that confirms ovulation, which is the progesterone metabolite PdG. Inito allows women to measure estrogen, LH, progesterone, and FSH on a single test strip. The company’s AI models interpret these hormone levels to reveal fertility patterns, track fertile days, and confirm ovulation.
Today, the startup has become a popular option for women looking to track fertility hormones, having analyzed more than 30 million fertility hormone data points since 2021. Inito is now evolving from a fertility tracker into a broader hormone and at-home health diagnostics platform, reinforcing its belief that healthcare should start at home.
The new funding will be invested in developing AI-engineered antibodies. Inito states this technology will allow for the development of new test types and improve the accuracy of existing ones. In traditional testing, antibodies that bind to target molecules are grown inside animals and manually screened, which is a slow and expensive process. Conventional antibodies also lack the sensitivity for at-home tests targeting many biomarkers.
Inito says AI-designed antibodies change this process entirely. Instead of raising antibodies in animals, they can be treated almost like software. The company predicts how proteins fold in three dimensions, designs synthetic antibodies using AI, and tests millions of variants virtually before creating any in a lab. This method produces antibodies that are more sensitive, consistent, and stable than those developed through traditional means.
For Inito, this will unlock the next generation of at-home tests. The company is already using these methods in research and development, with its wet-lab showing promising results. The broader vision is to redefine diagnostics. The goal is for individuals to understand what is happening inside their bodies at every life stage without being limited by clinic appointments or lab schedules. People should be able to measure, track, and get insights about their health from home with lab-grade confidence.
Inito plans to expand beyond a platform for those trying to conceive. Its reader and app will soon power tests for pregnancy, menopause, and broader at-home health monitoring. The long-term roadmap extends far beyond fertility, aiming to build a platform that can measure and interpret the full spectrum of hormones that shape health across a lifetime, including pregnancy progression, menopause, and markers like testosterone.
Part of the funding will also scale manufacturing and support global growth to meet growing demand in the United States and new international markets. This latest funding round was led by Bertelsmann India Investments and Fireside Ventures. The investment brings Inito’s total funding to approximately 45 million dollars. The company previously raised 6 million dollars in funding led by Fireside Ventures and 9 million dollars from Y Combinator, former Nurx CEO Varsha Rao, and a dozen physicians and family offices.